PSBench provides a benchmark for evaluating AI-predicted protein structures, addressing limitations of tools like AlphaFold by offering a trusted standard for model quality.

A central theme is the emergence of a scientific trust layer in AI biology, where validation and benchmarking determine real-world utility of predictive models.

The work was unveiled at NeurIPS 2025, underscoring the fusion of machine learning advances with structural biology.

This initiative shifts focus from simply predicting structures to judging whether predictions are reliable enough to guide experiments, a crucial step as AI-driven biology expands to complexes, interfaces, and interactions.

PSBench advances AI methods to assess model quality and determine which predictions can be trusted, creating a foundation for AI-driven biomedical discovery.

The dataset aggregates community efforts, including CASP, enabling AI models to score the reliability of other AI models and effectively introduce a trust layer for structural predictions.

It features 1.4 million protein models vetted by independent experts, aiming to improve reliability of AI-based protein structure evaluation for drug development against diseases like Alzheimer’s and cancer.

The release places PSBench in the broader context of protein folding research, highlighting how deep learning is transforming the field and the ongoing growth of AI tools in biomedicine.

Implications for drug discovery include better target prioritization, more efficient lab resource use, and potentially faster development of therapies for Alzheimer’s and cancer.

Jianlin (Jack) Cheng and colleagues built PSBench, leveraging CASP resources and in-house data, and presented the study at NeurIPS 2025 in San Diego.

The broader context notes AlphaFold’s expansion to model interactions and the growing scale of predicted structures, underscoring the need for rigorous benchmarking and governance in AI-driven biology.

PSBench complements existing tools by improving validation and triage of predictions, potentially reducing false confidence and speeding up drug discovery.